Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study
Annals of neurology, 2005•Wiley Online Library
We have shown previously that intraparenchymal infusion of glial cell line–derived
neurotrophic factor (GDNF) continuously into the posterior putamen in five Parkinson's
disease patients is safe and may represent a new treatment option. Here, we report a
continuation of this phase I study. After 2 years of continual GDNF infusion, there were no
serious clinical side effects and no significant detrimental effects on cognition. Patients
showed a 57% and 63% improvement in their off‐medication motor and activities of daily …
neurotrophic factor (GDNF) continuously into the posterior putamen in five Parkinson's
disease patients is safe and may represent a new treatment option. Here, we report a
continuation of this phase I study. After 2 years of continual GDNF infusion, there were no
serious clinical side effects and no significant detrimental effects on cognition. Patients
showed a 57% and 63% improvement in their off‐medication motor and activities of daily …
Abstract
We have shown previously that intraparenchymal infusion of glial cell line–derived neurotrophic factor (GDNF) continuously into the posterior putamen in five Parkinson's disease patients is safe and may represent a new treatment option. Here, we report a continuation of this phase I study. After 2 years of continual GDNF infusion, there were no serious clinical side effects and no significant detrimental effects on cognition. Patients showed a 57% and 63% improvement in their off‐medication motor and activities of daily living subscores of the Unified Parkinson's Disease Rating Scale, respectively, and health‐related quality‐of‐life measures (Parkinson's Disease Questionnaire–39 and Short Form–36) showed general improvement over time. Ann Neurol 2005;57:298–302
Wiley Online Library